ID19543A - Terapi penggantian hormon total - Google Patents

Terapi penggantian hormon total

Info

Publication number
ID19543A
ID19543A IDP973170A ID973170A ID19543A ID 19543 A ID19543 A ID 19543A ID P973170 A IDP973170 A ID P973170A ID 973170 A ID973170 A ID 973170A ID 19543 A ID19543 A ID 19543A
Authority
ID
Indonesia
Prior art keywords
replacement total
hormones
therapy replacement
therapy
total hormones
Prior art date
Application number
IDP973170A
Other languages
English (en)
Inventor
Edmund Chein Md
Original Assignee
Edmund Chein Md
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edmund Chein Md filed Critical Edmund Chein Md
Publication of ID19543A publication Critical patent/ID19543A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/61—Growth hormones [GH] (Somatotropin)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IDP973170A 1996-12-13 1997-09-12 Terapi penggantian hormon total ID19543A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/766,320 US5855920A (en) 1996-12-13 1996-12-13 Total hormone replacement therapy

Publications (1)

Publication Number Publication Date
ID19543A true ID19543A (id) 1998-07-23

Family

ID=25076088

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP973170A ID19543A (id) 1996-12-13 1997-09-12 Terapi penggantian hormon total

Country Status (8)

Country Link
US (1) US5855920A (id)
JP (1) JPH10298103A (id)
KR (1) KR19980064080A (id)
GB (1) GB2320190B (id)
HK (1) HK1009402A1 (id)
ID (1) ID19543A (id)
MY (1) MY128415A (id)
SG (1) SG78281A1 (id)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
CA2376797C (en) * 1999-06-11 2011-03-22 Watson Pharmaceuticals, Inc. Administration of non oral androgenic steroids to women
US7376700B1 (en) * 1999-08-23 2008-05-20 Wellcoaches Corporation Personal coaching system for clients with ongoing concerns such as weight loss
US6187750B1 (en) * 1999-08-25 2001-02-13 Everyoung Technologies, Inc. Method of hormone treatment for patients with symptoms consistent with multiple sclerosis
US6562790B2 (en) 2000-02-05 2003-05-13 Chein Edmund Y M Hormone therapy methods and hormone products for abating coronary artery blockage
US20020119191A1 (en) * 2000-04-24 2002-08-29 Hitoo Nishino Pharmaceutical or food composition for treatment or prevention of brain edema
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
WO2002011768A1 (en) 2000-08-03 2002-02-14 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20020155990A1 (en) * 2001-04-20 2002-10-24 Renasci, Inc., D/B/A Renasci Anti-Aging Center Method of optimizing growth hormone replacement
US20020156019A1 (en) * 2001-04-20 2002-10-24 Renasci, Inc., D/B/A Renasci Anti-Aging Center Method of optimizing growth hormone replacement
US20030040433A1 (en) * 2001-08-27 2003-02-27 Case Leslie C. Synergistic, layered, precious metal-base metal hydrogenation catalysts
US7179798B2 (en) * 2001-11-16 2007-02-20 Russell R. Roby Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US20040109844A1 (en) * 2002-08-28 2004-06-10 The Board Of Trustees Of The University Of Illinois Methods of treating age-related defects and diseases
CA2495882A1 (en) * 2002-08-29 2004-03-11 The Regents Of The University Of California Agents and methods for enhancing bone formation
US20040062794A1 (en) * 2002-09-30 2004-04-01 Lee Shulman 17Beta- estradiol/levonorgestrel transdermal patch for hormone replacement therapy
US7635673B2 (en) 2003-03-25 2009-12-22 The Board Of Trustees Of The University Of Illinois Methods of inhibiting tumor cell proliferation
US8883769B2 (en) * 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
US20040259852A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US20050065136A1 (en) * 2003-08-13 2005-03-24 Roby Russell R. Methods and compositions for the treatment of infertility using dilute hormone solutions
WO2005020928A2 (en) 2003-08-29 2005-03-10 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
AU2004283431B2 (en) 2003-10-10 2009-09-10 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
US20050239758A1 (en) * 2004-04-21 2005-10-27 Roby Russell R Hormone treatment of multiple sclerosis
US20050239757A1 (en) * 2004-04-21 2005-10-27 Roby Russell R Hormone treatment of macular degeneration
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
JP4852539B2 (ja) * 2004-06-22 2012-01-11 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 腫瘍細胞増殖をＦＯＸＭ１ｓｉＲＮＡによって阻害する方法
US20060025390A1 (en) * 2004-07-28 2006-02-02 Roby Russell R Treatment of hormone allergy and related symptoms and disorders
DE102004063752A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
US8916151B2 (en) * 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
NZ563946A (en) * 2005-06-03 2012-02-24 Acrux Dds Pty Ltd Testosterone containing non-occlusive transdermal drug delivery composition for application to the arm pit / axilla
DK1937276T3 (da) 2005-10-12 2013-02-11 Besins Healthcare Luxembourg Forbedret testosterongel og fremgangsmåde til anvendelse deraf
EP1993558B1 (en) 2006-02-27 2014-07-30 The Regents of The University of California Oxysterol compounds and the hedgehog pathway
WO2007109609A2 (en) * 2006-03-17 2007-09-27 The Board Of Trustees Of The University Of Illinois Method for inhibiting angiogenesis
NZ571460A (en) * 2006-04-21 2010-10-29 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
CA2673513A1 (en) 2006-12-19 2008-07-10 The Regents Of University Of California Inhibition of ppar gamma expression by specific osteogenic oxysterols
AU2008331808B2 (en) 2007-03-16 2014-08-21 The Regents Of The University Of California Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling
US20110190201A1 (en) * 2008-07-24 2011-08-04 Searete Llc Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
US20100022494A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
US20100061976A1 (en) * 2008-07-24 2010-03-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
US20100022487A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
US20100022497A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject
JP6912852B2 (ja) 2010-11-18 2021-08-04 ホワイト マウンテン ファーマ，インコーポレイテッド 対象における慢性または解決不能な疼痛を処置するための、および／または痛覚閾値を高めるための方法、およびこれに用いる医薬組成物
KR20150013232A (ko) 2012-05-07 2015-02-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 골형성 및 헤지호그 신호전달을 유도하고 지방생성을 억제하는 옥시스테롤 유사체 oxy133
JP2016517888A (ja) 2013-05-02 2016-06-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 骨選択的骨形成のオキシステロール骨標的薬剤
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
CN108289932A (zh) 2015-05-22 2018-07-17 D·D·格恩金 胞外dna作为神经变性的治疗靶点
US10953074B2 (en) * 2017-01-08 2021-03-23 Richard D. Lippman Composition and method for improving sensorineural hearing
US11730795B2 (en) 2017-08-09 2023-08-22 Intervene Immune Inc. Pharmaceuticals and dosing means for human aging reversal
AU2019209770A1 (en) 2018-01-16 2020-09-03 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898857A (en) * 1984-10-29 1990-02-06 Chaovanee Aroonsakul Treating control nervous system diseases
US4897389A (en) * 1984-10-29 1990-01-30 Chaovanee Aroonsakul Treating central nervous system diseases
US5017470A (en) * 1984-10-29 1991-05-21 Chaovanee Aroonsakul Method of diagnosing alzheimer's disease and senile dementia
US4898856A (en) * 1984-10-29 1990-02-06 Chaovanee Aroonsakul Method for treating central nervous system diseases
US4902680A (en) * 1984-10-29 1990-02-20 Chaovanee Aroonsakul Treating central nervous system diseases
US5391381A (en) * 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
DE69022722T2 (de) * 1989-03-10 1996-05-02 Endorecherche Inc Kombinationstherapie zur behandlung von estrogenempfindlichen erkrankungen.
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
HU222501B1 (hu) * 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
CA2152780A1 (en) * 1992-12-28 1994-07-07 Robert F. Casper Transdermal hormone replacement therapy
US5468736A (en) * 1993-02-25 1995-11-21 The Medical College Of Hampton Road Hormone replacement therapy
US6297212B1 (en) * 1994-05-31 2001-10-02 Gregory M. Fahy Growth hormone therapy and related methods and pharmaceutical compositions
US5563131A (en) * 1994-08-04 1996-10-08 Pherin Corporation Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
NZ280017A (en) * 1994-09-21 1997-06-24 Scotia Holdings Plc Use of n-6 or n-3 series essential fatty acid (efa), and optionally an oestrogen, to make a medicament to treat or prevent hormone replacement therapy (hrt) associated breast pain in peri- or postmenopausal women; medicaments containing the efa and estrogen.

Also Published As

Publication number Publication date
MY128415A (en) 2007-01-31
GB9715349D0 (en) 1997-09-24
GB2320190A (en) 1998-06-17
SG78281A1 (en) 2001-02-20
GB2320190B (en) 2001-08-15
JPH10298103A (ja) 1998-11-10
US5855920A (en) 1999-01-05
KR19980064080A (ko) 1998-10-07
HK1009402A1 (en) 1999-06-04

Similar Documents

Publication Publication Date Title
ID19543A (id) Terapi penggantian hormon total
DE69618624D1 (de) Inhaliervorrichtung
PT796628E (pt) Inalador
FI964298A0 (fi) Faestningsanordning foer baerbar apparat
ID23498A (id) Peranti inhalasi
DE69716012T2 (de) Kehlkopfmaske
DE69723202D1 (de) Inhalatoren
NO20002447D0 (no) Inhalasjonsanordning
DE69819387D1 (de) Kehlkopfmaske
DE69815569D1 (de) Kehlkopfmaske
DE69726189D1 (de) Mikrokeratom
DE69811803D1 (de) Beatmungstubus
DE69813257T2 (de) Selbstumfassendes atmungsgerät
DE69811655D1 (de) Inhalationsvorrichtung
DE19882496T1 (de) Unabhängiges Atemgerät
ID24275A (id) Terapi kombinasi
DE69735754D1 (de) Impedanz-abhängiger implantierbarer kardiovertierer defribillator
EE200000797A (et) Transfektsioonipartiklid
DE29705574U1 (de) Lufttechnischer Apparat
DE29620750U1 (de) Solarium
FI974374A0 (fi) Apparat traevarorkraan foer faestaenden fordon
UA1260S (uk) Інгалятор
ID19359A (id) Inhaler
DE29612699U1 (de) Inhaliergerät
FI974078A0 (fi) En apparat foer att maetae fotosyntesis